Heparin Market by Types (Low Molecular Weight Heparin, Ultra-Low Molecular Weight Heparin, and Unfractionated Heparin), Administrations (Intravenous and Subcutaneous), Applications (Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease, and Others), End-Users (Outpatient and Inpatient) and Regions (Asia Pacific, North America, Latin America, Europe and Middle East & Africa)- Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028
The global heparin market size was valued at USD 6.9 billion in 2020 and is anticipated to expand at a CAGR of 1.5% during the forecast period, 2021-2028. The growth of the market is attributed to the rising number of accidents along with their related surgeries and the increase in number of cardiovascular disorders & venous thromboembolism.
Heparin is a blood thinner medication used as an anticoagulant specifically used in the diagnosis of unstable angina and heart attacks. Heparin is normally injected into the patient’s vein or through the skin. They can be used for the treatment of blood clotting disorders. They can also be used in the prevention of blood clots during surgery, during blood transfusions, during dialysis, when collecting blood samples and when a person is paralyzed for long periods of time. Other applications include kidney dialysis machines and test tubes for their storage. According to the World Health Organization or the WHO along with the Centers for Disease Control and Prevention or the CDC, more than 900,000 people living in the United States of America have been affected by pulmonary embolism and deep vein thrombosis in 2018 and this will increase exponentially after the COVID-19 pandemic. The preliminary examination to treat these diseases is done with the help of heparin.
The COVID-19 pandemic has reduced the growth of the global heparin market initially. Researchers and scientists were not able to recognize the co-relation between the coronavirus and heparin. However, upon further research, they were able to identify that heparin can used for vaccination purposes against the coronavirus. This steered to hospitals, clinics, and healthcare laboratories to focus more on the development of heparin for the prevention and treatment of diseases and this led to its market growth in the later stages of the COVID-19 pandemic.
Market Trends, Drivers, Restraints, and Opportunities
- Increase in occurrences of cardiovascular diseases which can be treated by heparin diagnostics is the primary reason for the projection of boosting the global heparin market growth during the forecast period, 2021-2028.
- There has been a rapid growth in the investment & funding towards the research & development activities towards heparin from the biopharmaceutical companies, which propels the market expansion in the coming years.
- High prices for the development of heparin and high cost of services from the company’s perspective is anticipated to hinder the global heparin market growth. This becomes extremely difficult to function in developing countries such as India, South Africa and Brazil where there is limited healthcare infrastructure.
- Heparin is contraindicated with suspected instances such as the Vaccine-Induced Pro-thrombotic Immune Thrombocytopenia or VIPIT, which can increase the jeopardy of bleeding through the blood clots of the patient. This can hamper the heparin market growth.
- R&D activities along with studies have shown that unfractionated heparin being a varying chain sizing polymer, can be modified to countereffect certain diseases including the coronavirus. In October 2020, the WHO team had notified that the SARS-CoV-2 vaccination can be done on a certain chain size of heparin and can be mass-produced by the end of the year.
Scope of the Report
The report on the global heparin market size includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Heparin Market Size - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2020 |
|
Historic Data |
2018–2019 |
|
Forecast Period |
2021–2028 |
|
Segmentation |
Types (Low Molecular Weight Heparin, Ultra-Low Molecular Weight Heparin, and Unfractionated Heparin), Administrations (Intravenous and Subcutaneous), Applications (Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease, and Others), End-Users (Outpatient and Inpatient) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
GlaxoSmithKline plc; Pfizer Inc; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd; Aspen Holdings; B. Braun Medical Inc; Fresenius SE & Co KGaA; and Teva Pharmaceuticals Industries Ltd |
Global Heparin Market Segment Insights
Low molecular weight heparin segment is estimated to signify the largest market share
Based on types, the global heparin market is segmented into low molecular weight heparin, ultra-low molecular weight heparin, and unfractionated heparin. The low molecular weight heparin segment is expected to constitute the major share of the market in 2019 due to the more predictable and reliable anticoagulant effect with respect to the product. There has also been low incidence towards heparin induced thrombocytopenia which in turns increases the usage of low molecular weight heparin.
Meanwhile the ultra-low molecular weight heparin segment is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. The major reason attributing to this market growth is the commercialization of these products along with improved pharmaceutical effects.
Subcutaneous segment is projected to register a large market share
Based on administrations, the global heparin market is bifurcated into intravenous and subcutaneous. The subcutaneous segment is expected to constitute the major share of the market in 2019 and is anticipated to grow with a significant CAGR during the forecast period, 2021-2028 due to the lower costs associated to the patient’s hospitalization. This is also advantageous from the patient’s perspective owing to the increase preference in home care, reduced duration of diagnosis, and the ease in administration.
Coronary artery disease segment is anticipated to register a huge market share
On the basis of applications, the global heparin market is divided into venous thromboembolism, atrial fibrillation, renal impairment, coronary artery disease, and others. The coronary artery disease segment is expected to constitute the major share of the market in 2019. The major reason attributing to this market growth is the rising incidences of multiple heart-related diseases and disorders. One in every three American dies due to cardiovascular diseases and the coronary artery disease falls in this category.
Meanwhile the venous thromboembolism segment is anticipated to grow with a significant CAGR during the forecast period, 2021-2028. There has been a significant increase in the awareness of thrombosis and the treatment using heparin. There has also been websites and blogs specifically dedicated to these disorders and the preventive measures to take as well.
Outpatient segment is expected to propel a large market share
Based on end-users, the global heparin market is bifurcated into outpatient and inpatient. The outpatient segment is expected to constitute the major share of the market in 2019 and is anticipated to grow with a significant CAGR of 2.3% during the forecast period, 2021-2028 due to the lower cost of outpatients compared to that of inpatients. The efficacy for outpatients is also high and with research and development activities, this can only go higher from here.
North America is anticipated to dominate the market
On the basis of regions, the global heparin market is categorized as Asia Pacific, North America, Latin America, Europe and Middle East & Africa. The market in North America is expected to constitute the largest share in 2019. This regional market growth can be attributed to the growing research & development expenditure along with the rising in adoption of the latest technology. The demand of heparin is increasing rapidly in this region due to the presence of the major market players in the market, an advantage no other region has. The cost of expenditure is significantly lower in North America than that of other economies. However, the market in Asia Pacific is anticipated to expand at a significant CAGR during the forecast period, 2021-2028, as they have prioritized the cost-efficiency perspective of heparin combined with their growing population.
Segments
Segments Covered in the Report
The global heparin market size has been segmented in terms of
Types
- Low Molecular Weight Heparin
- Ultra-Low Molecular Weight Heparin
- Unfractionated Heparin
Administrations
- Intravenous
- Subcutaneous
Applications
- Venous Thromboembolism
- Atrial Fibrillation
- Renal Impairment
- Coronary Artery Disease
- Others
End-Users
- Outpatient
- Inpatient
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- GlaxoSmithKline plc
- Pfizer Inc
- Baxter
- Leo Pharma A/S
- Sanofi
- Dr. Reddy’s Laboratories Ltd
- Aspen Holdings
- B. Braun Medical Inc
- Fresenius SE & Co KGaA
- Teva Pharmaceuticals Industries Ltd
Competitive Landscape
Major players competing in the global heparin market are GlaxoSmithKline plc; Pfizer Inc; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd; Aspen Holdings; B. Braun Medical Inc; Fresenius SE & Co KGaA; and Teva Pharmaceuticals Industries Ltd. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Fresenius SE & Co KGaA launched heparin sodium in 2018 in the form of ready-to-administer non DEHP bags, improving their portfolio in the global heparin market.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Heparin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Heparin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Heparin Market - Supply Chain
4.5. Global Heparin Market Forecast
4.5.1. Heparin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Heparin Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Heparin Market Absolute $ Opportunity
5. Global Heparin Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Heparin Market Size and Volume Forecast by Types
5.3.1. Low Molecular Weight Heparin
5.3.2. Ultra-Low Molecular Weight Heparin
5.3.3. Unfractionated Heparin
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Heparin Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Heparin Market Size and Volume Forecast by Applications
6.3.1. Venous Thromboembolism
6.3.2. Atrial Fibrillation
6.3.3. Renal Impairment
6.3.4. Coronary Artery Disease
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Heparin Market Analysis and Forecast by End Users
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by End Users
7.2.2. Y-o-Y Growth Projections by End Users
7.3. Heparin Market Size and Volume Forecast by End Users
7.3.1. Outpatient
7.3.2. Inpatient
7.4. Absolute $ Opportunity Assessment by End Users
7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Heparin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Heparin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Heparin Demand Share Forecast, 2019-2026
9. North America Heparin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Heparin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Heparin Market Size and Volume Forecast by Types
9.4.1. Low Molecular Weight Heparin
9.4.2. Ultra-Low Molecular Weight Heparin
9.4.3. Unfractionated Heparin
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. North America Heparin Market Size and Volume Forecast by Applications
9.7.1. Venous Thromboembolism
9.7.2. Atrial Fibrillation
9.7.3. Renal Impairment
9.7.4. Coronary Artery Disease
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. North America Heparin Market Size and Volume Forecast by End Users
9.10.1. Outpatient
9.10.2. Inpatient
9.11. Basis Point Share (BPS) Analysis by End Users
9.12. Y-o-Y Growth Projections by End Users
9.13. Market Attractiveness/Growth Potential Analysis
9.13.1. By Country
9.13.2. By Product Type
9.13.3. By Application
9.14. North America Heparin Demand Share Forecast, 2019-2026
10. Latin America Heparin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Heparin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Heparin Market Size and Volume Forecast by Types
10.4.1. Low Molecular Weight Heparin
10.4.2. Ultra-Low Molecular Weight Heparin
10.4.3. Unfractionated Heparin
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Latin America Heparin Market Size and Volume Forecast by Applications
10.7.1. Venous Thromboembolism
10.7.2. Atrial Fibrillation
10.7.3. Renal Impairment
10.7.4. Coronary Artery Disease
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Latin America Heparin Market Size and Volume Forecast by End Users
10.10.1. Outpatient
10.10.2. Inpatient
10.11. Basis Point Share (BPS) Analysis by End Users
10.12. Y-o-Y Growth Projections by End Users
10.13. Market Attractiveness/Growth Potential Analysis
10.13.1. By Country
10.13.2. By Product Type
10.13.3. By Application
10.14. Latin America Heparin Demand Share Forecast, 2019-2026
11. Europe Heparin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Heparin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Heparin Market Size and Volume Forecast by Types
11.4.1. Low Molecular Weight Heparin
11.4.2. Ultra-Low Molecular Weight Heparin
11.4.3. Unfractionated Heparin
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Europe Heparin Market Size and Volume Forecast by Applications
11.7.1. Venous Thromboembolism
11.7.2. Atrial Fibrillation
11.7.3. Renal Impairment
11.7.4. Coronary Artery Disease
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Europe Heparin Market Size and Volume Forecast by End Users
11.10.1. Outpatient
11.10.2. Inpatient
11.11. Basis Point Share (BPS) Analysis by End Users
11.12. Y-o-Y Growth Projections by End Users
11.13. Market Attractiveness/Growth Potential Analysis
11.13.1. By Country
11.13.2. By Product Type
11.13.3. By Application
11.14. Europe Heparin Demand Share Forecast, 2019-2026
12. Asia Pacific Heparin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Heparin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Heparin Market Size and Volume Forecast by Types
12.4.1. Low Molecular Weight Heparin
12.4.2. Ultra-Low Molecular Weight Heparin
12.4.3. Unfractionated Heparin
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Asia Pacific Heparin Market Size and Volume Forecast by Applications
12.7.1. Venous Thromboembolism
12.7.2. Atrial Fibrillation
12.7.3. Renal Impairment
12.7.4. Coronary Artery Disease
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Asia Pacific Heparin Market Size and Volume Forecast by End Users
12.10.1. Outpatient
12.10.2. Inpatient
12.11. Basis Point Share (BPS) Analysis by End Users
12.12. Y-o-Y Growth Projections by End Users
12.13. Market Attractiveness/Growth Potential Analysis
12.13.1. By Country
12.13.2. By Product Type
12.13.3. By Application
12.14. Asia Pacific Heparin Demand Share Forecast, 2019-2026
13. Middle East & Africa Heparin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Middle East & Africa Average Pricing Analysis
13.2. Middle East & Africa Heparin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Heparin Market Size and Volume Forecast by Types
13.4.1. Low Molecular Weight Heparin
13.4.2. Ultra-Low Molecular Weight Heparin
13.4.3. Unfractionated Heparin
13.5. Basis Point Share (BPS) Analysis by Types
13.6. Y-o-Y Growth Projections by Types
13.7. Middle East & Africa Heparin Market Size and Volume Forecast by Applications
13.7.1. Venous Thromboembolism
13.7.2. Atrial Fibrillation
13.7.3. Renal Impairment
13.7.4. Coronary Artery Disease
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Applications
13.9. Y-o-Y Growth Projections by Applications
13.10. Middle East & Africa Heparin Market Size and Volume Forecast by End Users
13.10.1. Outpatient
13.10.2. Inpatient
13.11. Basis Point Share (BPS) Analysis by End Users
13.12. Y-o-Y Growth Projections by End Users
13.13. Market Attractiveness/Growth Potential Analysis
13.13.1. By Country
13.13.2. By Product Type
13.13.3. By Application
13.14. Middle East & Africa Heparin Demand Share Forecast, 2019-2026
14. Competition Landscape
14.1. Global Heparin Market: Market Share Analysis
14.2. Heparin Distributors and Customers
14.3. Heparin Market: Competitive Dashboard
14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline plc
14.4.2. Pfizer Inc
14.4.3. Baxter
14.4.4. Leo Pharma A/S
14.4.5. Sanofi
2. Assumptions and Acronyms Used
3. Research Methodology
4. Heparin Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Heparin Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Heparin Market - Supply Chain
4.5. Global Heparin Market Forecast
4.5.1. Heparin Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Heparin Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Heparin Market Absolute $ Opportunity
5. Global Heparin Market Analysis and Forecast by Types
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Types
5.2.2. Y-o-Y Growth Projections by Types
5.3. Heparin Market Size and Volume Forecast by Types
5.3.1. Low Molecular Weight Heparin
5.3.2. Ultra-Low Molecular Weight Heparin
5.3.3. Unfractionated Heparin
5.4. Absolute $ Opportunity Assessment by Types
5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Heparin Market Analysis and Forecast by Applications
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Applications
6.2.2. Y-o-Y Growth Projections by Applications
6.3. Heparin Market Size and Volume Forecast by Applications
6.3.1. Venous Thromboembolism
6.3.2. Atrial Fibrillation
6.3.3. Renal Impairment
6.3.4. Coronary Artery Disease
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Applications
6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Heparin Market Analysis and Forecast by End Users
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by End Users
7.2.2. Y-o-Y Growth Projections by End Users
7.3. Heparin Market Size and Volume Forecast by End Users
7.3.1. Outpatient
7.3.2. Inpatient
7.4. Absolute $ Opportunity Assessment by End Users
7.5. Market Attractiveness/Growth Potential Analysis by End Users
8. Global Heparin Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Heparin Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Heparin Demand Share Forecast, 2019-2026
9. North America Heparin Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Heparin Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Heparin Market Size and Volume Forecast by Types
9.4.1. Low Molecular Weight Heparin
9.4.2. Ultra-Low Molecular Weight Heparin
9.4.3. Unfractionated Heparin
9.5. Basis Point Share (BPS) Analysis by Types
9.6. Y-o-Y Growth Projections by Types
9.7. North America Heparin Market Size and Volume Forecast by Applications
9.7.1. Venous Thromboembolism
9.7.2. Atrial Fibrillation
9.7.3. Renal Impairment
9.7.4. Coronary Artery Disease
9.7.5. Others
9.8. Basis Point Share (BPS) Analysis by Applications
9.9. Y-o-Y Growth Projections by Applications
9.10. North America Heparin Market Size and Volume Forecast by End Users
9.10.1. Outpatient
9.10.2. Inpatient
9.11. Basis Point Share (BPS) Analysis by End Users
9.12. Y-o-Y Growth Projections by End Users
9.13. Market Attractiveness/Growth Potential Analysis
9.13.1. By Country
9.13.2. By Product Type
9.13.3. By Application
9.14. North America Heparin Demand Share Forecast, 2019-2026
10. Latin America Heparin Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Heparin Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Heparin Market Size and Volume Forecast by Types
10.4.1. Low Molecular Weight Heparin
10.4.2. Ultra-Low Molecular Weight Heparin
10.4.3. Unfractionated Heparin
10.5. Basis Point Share (BPS) Analysis by Types
10.6. Y-o-Y Growth Projections by Types
10.7. Latin America Heparin Market Size and Volume Forecast by Applications
10.7.1. Venous Thromboembolism
10.7.2. Atrial Fibrillation
10.7.3. Renal Impairment
10.7.4. Coronary Artery Disease
10.7.5. Others
10.8. Basis Point Share (BPS) Analysis by Applications
10.9. Y-o-Y Growth Projections by Applications
10.10. Latin America Heparin Market Size and Volume Forecast by End Users
10.10.1. Outpatient
10.10.2. Inpatient
10.11. Basis Point Share (BPS) Analysis by End Users
10.12. Y-o-Y Growth Projections by End Users
10.13. Market Attractiveness/Growth Potential Analysis
10.13.1. By Country
10.13.2. By Product Type
10.13.3. By Application
10.14. Latin America Heparin Demand Share Forecast, 2019-2026
11. Europe Heparin Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Heparin Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Heparin Market Size and Volume Forecast by Types
11.4.1. Low Molecular Weight Heparin
11.4.2. Ultra-Low Molecular Weight Heparin
11.4.3. Unfractionated Heparin
11.5. Basis Point Share (BPS) Analysis by Types
11.6. Y-o-Y Growth Projections by Types
11.7. Europe Heparin Market Size and Volume Forecast by Applications
11.7.1. Venous Thromboembolism
11.7.2. Atrial Fibrillation
11.7.3. Renal Impairment
11.7.4. Coronary Artery Disease
11.7.5. Others
11.8. Basis Point Share (BPS) Analysis by Applications
11.9. Y-o-Y Growth Projections by Applications
11.10. Europe Heparin Market Size and Volume Forecast by End Users
11.10.1. Outpatient
11.10.2. Inpatient
11.11. Basis Point Share (BPS) Analysis by End Users
11.12. Y-o-Y Growth Projections by End Users
11.13. Market Attractiveness/Growth Potential Analysis
11.13.1. By Country
11.13.2. By Product Type
11.13.3. By Application
11.14. Europe Heparin Demand Share Forecast, 2019-2026
12. Asia Pacific Heparin Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Heparin Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Heparin Market Size and Volume Forecast by Types
12.4.1. Low Molecular Weight Heparin
12.4.2. Ultra-Low Molecular Weight Heparin
12.4.3. Unfractionated Heparin
12.5. Basis Point Share (BPS) Analysis by Types
12.6. Y-o-Y Growth Projections by Types
12.7. Asia Pacific Heparin Market Size and Volume Forecast by Applications
12.7.1. Venous Thromboembolism
12.7.2. Atrial Fibrillation
12.7.3. Renal Impairment
12.7.4. Coronary Artery Disease
12.7.5. Others
12.8. Basis Point Share (BPS) Analysis by Applications
12.9. Y-o-Y Growth Projections by Applications
12.10. Asia Pacific Heparin Market Size and Volume Forecast by End Users
12.10.1. Outpatient
12.10.2. Inpatient
12.11. Basis Point Share (BPS) Analysis by End Users
12.12. Y-o-Y Growth Projections by End Users
12.13. Market Attractiveness/Growth Potential Analysis
12.13.1. By Country
12.13.2. By Product Type
12.13.3. By Application
12.14. Asia Pacific Heparin Demand Share Forecast, 2019-2026
13. Middle East & Africa Heparin Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Middle East & Africa Average Pricing Analysis
13.2. Middle East & Africa Heparin Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Heparin Market Size and Volume Forecast by Types
13.4.1. Low Molecular Weight Heparin
13.4.2. Ultra-Low Molecular Weight Heparin
13.4.3. Unfractionated Heparin
13.5. Basis Point Share (BPS) Analysis by Types
13.6. Y-o-Y Growth Projections by Types
13.7. Middle East & Africa Heparin Market Size and Volume Forecast by Applications
13.7.1. Venous Thromboembolism
13.7.2. Atrial Fibrillation
13.7.3. Renal Impairment
13.7.4. Coronary Artery Disease
13.7.5. Others
13.8. Basis Point Share (BPS) Analysis by Applications
13.9. Y-o-Y Growth Projections by Applications
13.10. Middle East & Africa Heparin Market Size and Volume Forecast by End Users
13.10.1. Outpatient
13.10.2. Inpatient
13.11. Basis Point Share (BPS) Analysis by End Users
13.12. Y-o-Y Growth Projections by End Users
13.13. Market Attractiveness/Growth Potential Analysis
13.13.1. By Country
13.13.2. By Product Type
13.13.3. By Application
13.14. Middle East & Africa Heparin Demand Share Forecast, 2019-2026
14. Competition Landscape
14.1. Global Heparin Market: Market Share Analysis
14.2. Heparin Distributors and Customers
14.3. Heparin Market: Competitive Dashboard
14.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline plc
14.4.2. Pfizer Inc
14.4.3. Baxter
14.4.4. Leo Pharma A/S
14.4.5. Sanofi
Segments Covered in the Report
The global heparin market size has been segmented in terms of
Types
- Low Molecular Weight Heparin
- Ultra-Low Molecular Weight Heparin
- Unfractionated Heparin
Administrations
- Intravenous
- Subcutaneous
Applications
- Venous Thromboembolism
- Atrial Fibrillation
- Renal Impairment
- Coronary Artery Disease
- Others
End-Users
- Outpatient
- Inpatient
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- GlaxoSmithKline plc
- Pfizer Inc
- Baxter
- Leo Pharma A/S
- Sanofi
- Dr. Reddy’s Laboratories Ltd
- Aspen Holdings
- B. Braun Medical Inc
- Fresenius SE & Co KGaA
- Teva Pharmaceuticals Industries Ltd
Major players competing in the global heparin market are GlaxoSmithKline plc; Pfizer Inc; Baxter; Leo Pharma A/S; Sanofi; Dr. Reddy’s Laboratories Ltd; Aspen Holdings; B. Braun Medical Inc; Fresenius SE & Co KGaA; and Teva Pharmaceuticals Industries Ltd. These market players are involved in several business strategies such as mergers, acquisitions partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. Fresenius SE & Co KGaA launched heparin sodium in 2018 in the form of ready-to-administer non DEHP bags, improving their portfolio in the global heparin market.
Our Clients
Related Reports
Some other reports from this category!
